PDF(Pubmed)
Abstract：
We present the case of a 61-year-old man who developed coronavirus disease 2019 (COVID-19) and died during treatment for relapsing polychondritis. The patient was intubated and treated with steroid pulse therapy, remdecivir, antibacterial agents, baricitinib, and tocilizumab. However, his respiratory condition worsened, and he died 108 days after disease onset. An autopsy revealed diffuse alveolar damage in the fibrotic phase in all lung lobes, diffuse pulmonary ossification, and cytomegalovirus-infected cells in the middle lobe of the right lung. We herein discuss the clinical features and pathological findings of COVID-19 in immunosuppressed patients.
摘要：
我们介绍了一名61岁男子的病例，他患上了2019年冠状病毒病（COVID-19），在复发性多软骨炎治疗期间死亡。病人接受了气管插管并接受了类固醇脉冲治疗,remdecvir,抗菌剂，baricitinib,和托珠单抗。然而,他的呼吸状况恶化了,他在发病108天后死亡.尸检显示所有肺叶在纤维化阶段弥漫性肺泡损伤，弥漫性肺骨化,和右肺中叶巨细胞病毒感染的细胞。我们在此讨论COVID-19在免疫抑制患者中的临床特征和病理发现。
